PL3478843T3 - Oligonukleotydy zawierające zmodyfikowane nukleozydy - Google Patents
Oligonukleotydy zawierające zmodyfikowane nukleozydyInfo
- Publication number
- PL3478843T3 PL3478843T3 PL17740201T PL17740201T PL3478843T3 PL 3478843 T3 PL3478843 T3 PL 3478843T3 PL 17740201 T PL17740201 T PL 17740201T PL 17740201 T PL17740201 T PL 17740201T PL 3478843 T3 PL3478843 T3 PL 3478843T3
- Authority
- PL
- Poland
- Prior art keywords
- oligonucleotides
- modified nucleosides
- nucleosides
- modified
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 125000003835 nucleoside group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
- C12N2330/31—Libraries, arrays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/117—Modifications characterised by incorporating modified base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/205—Aptamer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357623P | 2016-07-01 | 2016-07-01 | |
| US201662437592P | 2016-12-21 | 2016-12-21 | |
| EP17740201.3A EP3478843B1 (en) | 2016-07-01 | 2017-06-30 | Oligonucleotides comprising modified nucleosides |
| PCT/US2017/040299 WO2018005974A1 (en) | 2016-07-01 | 2017-06-30 | Oligonucleotides comprising modified nucleosides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3478843T3 true PL3478843T3 (pl) | 2022-01-31 |
Family
ID=59351104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17740201T PL3478843T3 (pl) | 2016-07-01 | 2017-06-30 | Oligonukleotydy zawierające zmodyfikowane nukleozydy |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10927380B2 (pl) |
| EP (2) | EP3913058A1 (pl) |
| JP (2) | JP7203613B2 (pl) |
| KR (2) | KR102501963B1 (pl) |
| CN (1) | CN109312346B (pl) |
| AU (1) | AU2017290804B2 (pl) |
| BR (1) | BR112018075869A8 (pl) |
| CA (1) | CA3027626A1 (pl) |
| DK (1) | DK3478843T3 (pl) |
| ES (1) | ES2886639T3 (pl) |
| IL (3) | IL291931B2 (pl) |
| MX (1) | MX2018014771A (pl) |
| PL (1) | PL3478843T3 (pl) |
| RU (2) | RU2763470C2 (pl) |
| SG (2) | SG11201811199QA (pl) |
| TW (1) | TWI770036B (pl) |
| WO (1) | WO2018005974A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021202376A1 (en) | 2020-03-30 | 2021-10-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs |
| WO2022043924A1 (en) * | 2020-08-28 | 2022-03-03 | Galderma Holding SA | Novel x-aptamers for the use in detection of snap25 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| US5719273A (en) * | 1993-06-14 | 1998-02-17 | Nexstar Pharmaceuticals, Inc. | Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide |
| US5945527A (en) * | 1996-05-30 | 1999-08-31 | Nexstar Pharmaceuticals, Inc. | Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide |
| US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
| JP3978187B2 (ja) | 2002-03-19 | 2007-09-19 | 富士通株式会社 | 機能性分子及びその製造方法 |
| AU2007205974A1 (en) | 2006-01-17 | 2007-07-26 | Somalogic, Incorporated | Multiplexed analyses of test samples |
| CN101573446B (zh) | 2006-11-14 | 2013-07-17 | 力博美科股份有限公司 | 针对中期因子的适体及其应用 |
| US7855054B2 (en) | 2007-01-16 | 2010-12-21 | Somalogic, Inc. | Multiplexed analyses of test samples |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| JP5750209B2 (ja) | 2007-03-16 | 2015-07-15 | アプタ バイオサイエンス リミテッド | 機能性分子、機能性分子合成用アミダイド、及び標的物質解析方法 |
| CN101809167B (zh) | 2007-07-17 | 2015-04-01 | 私募蛋白质体公司 | 产生具有改良的解离速率的适配体的方法 |
| JP5195757B2 (ja) | 2007-08-31 | 2013-05-15 | 富士通株式会社 | 核酸合成用ダイマーアミダイド及び核酸合成方法 |
| JP4499141B2 (ja) | 2007-09-05 | 2010-07-07 | 富士通株式会社 | 修飾核酸合成用アミダイド及び修飾核酸合成方法 |
| RU2401306C2 (ru) * | 2008-12-17 | 2010-10-10 | Научно-исследовательский институт Физико-химической биологии имени А.Н. Белозерского Московского Государственного Университета имени М.В. Ломоносова | Аптамерный олигонуклеотид - прямой ингибитор тромбина |
| US8569252B2 (en) * | 2009-04-15 | 2013-10-29 | Postech Academy-Industry Foundation | Nucleolin specific aptamer and use thereof |
| AU2011223527B2 (en) * | 2010-03-03 | 2014-11-13 | Somalogic Operating Co., Inc. | Aptamers to 4-1BB and their use in treating diseases and disorders |
| ES2629183T3 (es) * | 2011-03-10 | 2017-08-07 | Somalogic, Inc. | Aptámeros para diagnóstico de Clostridium difficile |
| CN104379764B (zh) | 2012-03-28 | 2018-04-06 | 私募蛋白质体公司 | Pdgf和vegf的适体及它们在治疗pdgf和vegf介导的病状中的用途 |
| SG11201507335QA (en) | 2013-03-14 | 2015-10-29 | Somalogic Inc | Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions |
| JP6506768B2 (ja) * | 2013-09-24 | 2019-04-24 | ソマロジック・インコーポレーテッド | 多重アプタマー標的の検出 |
| NZ736753A (en) | 2013-10-11 | 2018-11-30 | Dow Agrosciences Llc | Aqueous herbicidal concentrates |
| US9938314B2 (en) * | 2013-11-21 | 2018-04-10 | Somalogic, Inc. | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto |
| ES2764669T3 (es) * | 2014-02-18 | 2020-06-04 | Somalogic Inc | Composiciones y métodos para la detección de microorganismos |
| WO2015153860A1 (en) * | 2014-04-04 | 2015-10-08 | Somalogic, Inc. | Glomerular filtration rate biomarkers and uses thereof |
| NO2718257T3 (pl) * | 2014-05-30 | 2018-04-14 | ||
| US20170335395A1 (en) * | 2014-10-27 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | A parkinson's disease diagnostic biomarker panel |
| TWI695068B (zh) * | 2014-11-24 | 2020-06-01 | 美商身體邏輯股份有限公司 | 用於結合生長分化因子１１的核酸化合物 |
-
2017
- 2017-06-30 EP EP21174810.8A patent/EP3913058A1/en active Pending
- 2017-06-30 CA CA3027626A patent/CA3027626A1/en active Pending
- 2017-06-30 IL IL291931A patent/IL291931B2/en unknown
- 2017-06-30 PL PL17740201T patent/PL3478843T3/pl unknown
- 2017-06-30 SG SG11201811199QA patent/SG11201811199QA/en unknown
- 2017-06-30 IL IL311294A patent/IL311294A/en unknown
- 2017-06-30 EP EP17740201.3A patent/EP3478843B1/en active Active
- 2017-06-30 ES ES17740201T patent/ES2886639T3/es active Active
- 2017-06-30 KR KR1020187036330A patent/KR102501963B1/ko active IP Right Grant
- 2017-06-30 RU RU2019102588A patent/RU2763470C2/ru active
- 2017-06-30 AU AU2017290804A patent/AU2017290804B2/en active Active
- 2017-06-30 US US16/307,520 patent/US10927380B2/en active Active
- 2017-06-30 DK DK17740201.3T patent/DK3478843T3/da active
- 2017-06-30 JP JP2018566956A patent/JP7203613B2/ja active Active
- 2017-06-30 BR BR112018075869A patent/BR112018075869A8/pt unknown
- 2017-06-30 MX MX2018014771A patent/MX2018014771A/es unknown
- 2017-06-30 RU RU2021137915A patent/RU2021137915A/ru unknown
- 2017-06-30 WO PCT/US2017/040299 patent/WO2018005974A1/en unknown
- 2017-06-30 CN CN201780036021.0A patent/CN109312346B/zh active Active
- 2017-06-30 TW TW106121878A patent/TWI770036B/zh active
- 2017-06-30 KR KR1020237005478A patent/KR20230031972A/ko not_active Application Discontinuation
- 2017-06-30 SG SG10201911369PA patent/SG10201911369PA/en unknown
-
2018
- 2018-12-20 IL IL263852A patent/IL263852B/en unknown
-
2020
- 2020-12-18 US US17/126,330 patent/US11578330B2/en active Active
-
2022
- 2022-12-27 JP JP2022209677A patent/JP7531574B2/ja active Active
-
2023
- 2023-01-12 US US18/153,428 patent/US20230313202A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201905396B (en) | Trans-replicating rna | |
| HK1258758A1 (zh) | 分支的寡核苷酸 | |
| IL268422A (en) | Targeted oligonucleotides | |
| IL256634A (en) | Therapeutic oligonucleotides | |
| HK1252970A1 (zh) | 確定的多偶聯寡核苷酸 | |
| IL257091B (en) | Targeted oligonucleotides | |
| HK1257273A1 (zh) | 包含免疫刺激性寡核苷酸的組合物 | |
| GB201503408D0 (en) | Oligonucleotides | |
| GB201507926D0 (en) | Improved treatments using oligonucleotides | |
| GB201504124D0 (en) | Oligonucleotides | |
| SG10201913477UA (en) | G-quadruplex-containing antisense oligonucleotides | |
| GB201517241D0 (en) | DNA modification | |
| SG10201609048RA (en) | Antisense oligonucleotides | |
| IL273274A (en) | Nucleoside modified phosphoramidites | |
| IL263852B (en) | Oligonucleotides containing modified nucleosides | |
| PL3329004T3 (pl) | Terapeutyczne oligonukleotydy | |
| SG11201700652PA (en) | Modified antimir-138 oligonucleotides | |
| SG11202004757RA (en) | Dna polymerases | |
| SG11202001495VA (en) | Spirothietane nucleosides | |
| GB201714330D0 (en) | Oligonucleotides | |
| PT3318817T (pt) | Aquecedor | |
| GB201516505D0 (en) | Antisense oligonucleotides | |
| GB201508733D0 (en) | Antisense oligonucleotides | |
| GB201515680D0 (en) | Heater | |
| IL238379A0 (en) | heater |